Juvenile Idiopathic Arthritis (JIA) subtypes that correspond to the former Juvenile Rheumatoid Arthritis (JRA) classification system who are treated by a participating pediatric rheumatologist and treated with either celecoxib or an nsNSAID; celecoxib or nsNSAID must be new treatment or recent initiation (within last 6 months).
Read more: http://www.clinicaltrials.gov/ct2/show/NCT00688545?cond=%22Arthritis%22&lup_s=07/14/2011&lup_d=30
